You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Alnylam Pharmaceuticals, Inc. authorized a program to repurchase up to $1.0 billion of common stock, with approximately $500 million anticipated by the end of 2026 and the balance during 2027. Tolga Tanguler will depart in December 2026.
Alnylam’s Q3 product revenue grew 52% year-over-year to approximately $1.3 billion. TTR sales are expected at the low end of $4.2 billion to $4.5 billion, while Triton-CM enrollment rose 500 patients to approximately 2,250 without changing approximately 2030 launch timing.
Alnylam reported third-quarter 2026 global net product revenue of $1.13 billion for AMVUTTRA and $19.6 million for ONPATTRO, while expanding TRITON-CM nucresiran enrollment to approximately 2,250 patients.
Alnylam Pharmaceuticals reported Third Quarter 2026 global net product revenues of $1,292 Million, up 52%; expanded TRITON-CM target enrollment to 2,250 patients and expects brezosiran pivotal study initiation in 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Alnylam delivered strong Q3 product-revenue growth, positive GAAP net income, higher cash, and positive pipeline updates including expanded TRITON-CM enrollment, encouraging brezosiran data, HELIOS-B analyses, mivelsiran progress, and an upcoming cemdisiran PDUFA event. However, demand conversion is lagging expectations, 2026 TTR sales are expected at the low end of guidance, margins and operating income declined, proposed 340B and UnitedHealth policy changes create access and ordering risks, and 2027 revenue guidance was deferred.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| AMVUTTRA global net product revenues | $1.13B | FY2026 Q3 | +64.9% |
|
|
|||
| GIVLAARI global net product revenues | $89.49M | FY2026 Q3 | +21.1% |
|
|
|||
| OXLUMO global net product revenues | $52.5M | FY2026 Q3 | -0.6% |
|
|
|||
| Total TTR net product revenues | $1.15B | FY2026 Q3 | +58.8% |
|
|
|||
| ONPATTRO global net product revenues | $18M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALNY
this stock
Alnylam Pharmaceuticals, Inc.
|
$22.11B | -58.5% | +22.9% | 8.5 | 4.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Alnylam Pharmaceuticals, Inc. authorized a program to repurchase up to $1.0 billion of common stock, with approximately $500 million anticipated by the end of 2026 and the balance during 2027. Tolga Tanguler will depart in December 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALNY | +5.8% | -28.8% | -44.2% | +0.0% | -58.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.3% | -27.7% | -44.7% | +0.2% | -69.1% |
